| Name | Title | Contact Details |
|---|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
Nautilus Biosciences Canada is a Charlottetown, PE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mixhers is a company that provides supplements designed specifically for womens health and wellness, with each product carefully crafted to support women in all stages of life.
New Century INfusion Solutions is a Brea, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Fisher Wallace Stimulator® is a wearable neurostimulation device cleared by the FDA to treat depression, anxiety and insomnia. During each 20-minute treatment session, the device gently stimulates the brain to produce serotonin and other neurochemi...